Staidson (Beijing) BioPharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Wang Chao

Chief executive officer

CN¥1.4m

Total compensation

CEO salary percentage	n/a
CEO tenure	3.2yrs
CEO ownership	0.08%
Management average tenure	no data
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO

Wang Chao (42 yo)

3.2yrs

Tenure

CN¥1,362,100

Compensation

Mr. Wang Chao is General Manager of Staidson (Beijing) BioPharmaceuticals Co. Ltd. from August 2021.

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhi Wen Zhou	Chairman	15.4yrs	CN¥1.30m	1.1% CN¥ 41.7m
Tao Li	Supervisor	13.7yrs	CN¥168.10k	no data
Hongshan Zhang	Chairman of Supervisory Board	6.1yrs	CN¥240.00k	0.098% CN¥ 3.7m
Rong Qin Zhang	Non-Independent Director	6.1yrs	CN¥1.70m	0.21% CN¥ 7.8m
Ying Sun	Independent Director	6.1yrs	CN¥136.80k	no data
Lianchun Yang	Non-Independent Director	3.2yrs	CN¥1.60m	0.075% CN¥ 2.8m
Li Zhao	Independent Director	3.2yrs	CN¥136.80k	no data
Jiajun Zhao	Independent Director	3.2yrs	CN¥136.80k	no data
Hong Zheng	Employee Supervisor	3.2yrs	no data	0.024% CN¥ 907.3k
Xiaoyan Wang	Director	2.1yrs	no data	no data

4.6yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 300204's board of directors are considered experienced (4.6 years average tenure).

Staidson (Beijing) BioPharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

High number of new directors

Recent updates

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.001 (vs CN¥0.22 loss in 2Q 2023)

New minor risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.10 loss in 1Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: CN¥0.84 loss per share (vs CN¥0.41 loss in FY 2022)

New major risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.14 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.41 loss per share (vs CN¥0.29 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.14 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.094 loss in 2Q 2021)

Full year 2021 earnings released: CN¥0.29 loss per share (vs CN¥0.28 loss in FY 2020)

High number of new directors

Third quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.05 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.094 loss per share (vs CN¥0.11 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥8.02

New 90-day low: CN¥8.59

New 90-day low: CN¥9.90

Third quarter earnings released

New 90-day low: CN¥10.52

New 90-day low: CN¥10.73

First half earnings released

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥13.02

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age